Targeted Protein Degradation by Small Molecules

Annual Review of Pharmacology and Toxicology

Volumn 57, Issue , 2017, Pages 107-123

  Bondeson, Daniel P ^a   Crews, Craig M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chemical knockdown; IMiDs; PROTACs; protein degradation; ubiquitin proteasome system

Indexed keywords

3 (5 AMINO 2 METHYL 4 OXOQUINAZOLIN 3(4H) YL)PIPERIDINE 2,6 DIONE; AGENTS AFFECTING PROTEIN METABOLISM; ANDROGEN RECEPTOR; ASUNAPREVIR; AUXIN; BESTATIN; BIRABRESIB; BOSUTINIB; CELL PROTEIN; DASATINIB; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; IMATINIB; IMMUNOMODULATING AGENT; INTERFERON REGULATORY FACTOR 4; LENALIDOMIDE; LIGAND; NATURAL PRODUCT; OVALICIN; POMALIDOMIDE; PROTEIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEOLYSIS TARGETING CHIMERIC MOLECULE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE 2; RU 59063; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG; OLIGOPEPTIDE;

CHIMERA; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; HYDROPHOBICITY; MEDICAL RESEARCH; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN HOMEOSTASIS; REVIEW; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; PROCEDURES; TRENDS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; OLIGOPEPTIDES; PROTEINS; PROTEOLYSIS; SMALL MOLECULE LIBRARIES;

EID: 85009097043     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010715-103507     Document Type: Review

References (112)

1. Copeland RA. 2015. The drug-target residence time model: a 10-year retrospective. Nat. Rev. Drug Discov. 15(2):87-95
2. Russ AP, Lampel S. 2005. The druggable genome: an update. Drug Discov. Today 10(23-24):1607-10
3. Conde J, Artzi N. 2015. Are RNAi and miRNA therapeutics truly dead Trends Biotechnol. 33(3):141-44
4. Clague MJ,Heride C,Urbé S. 2015. The demographics of the ubiquitin system. Trends Cell Biol. 25:417-26
5. Deshaies RJ, Joazeiro CAP. 2009. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 78:399-434
6. Ciechanover A. 2015. The unravelling of the ubiquitin system. Nat. Rev. Mol. Cell. Biol. 16(5):322-24
7. He C, Klionsky DJ. 2009. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 43:67-93
8. Kaushik S, Cuervo AM. 2012. Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends Cell Biol. 22(8):407-17
9. Liang J, Shang Y. 2013. Estrogen and cancer. Annu. Rev. Physiol. 75:225-40
10. Dauvois S,Danielian PS,White R, ParkerMG.1992. Antiestrogen ICI-164,384 reduces cellular estrogen receptor content by increasing its turnover. PNAS 89(9):4037-41
11. Wakeling AE, DukesM, Bowler J. 1991. A potent specific pure antiestrogen with clinical potential. Am. Assoc. Cancer Res. 3867-73
12. Lai A, KahramanM,Govek S, Nagasawa J, Bonnefous C, et al. 2015. Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. J. Med. Chem. 58(12):4888-904
13. Kieser KJ, Kim DW, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA. 2010. Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs). J. Med. Chem. 53(8):3320-29
14. Govek SP, Nagasawa JY, Douglas KL, Lai AG, Kahraman M, et al. 2015. Optimization of an indazole series of selective estrogen receptor degraders: tumor regression in a tamoxifen-resistant breast cancer xenograft. Bioorg. Med. Chem. Lett. 25(22):5163-67
15. Callis R, Rabow A, Tonge M, Bradbury R, Challinor M, et al. 2015. A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs). J. Biomol. Screen. 20(6):748-59
16. De Savi C, Bradbury RH, Rabow AA, Norman RA, de Almeida C, et al. 2015. Optimization of a novel binding motif to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregutor and antagonist. J. Med. Chem. 58(20):8128-40
17. Suzuki N, Liu X, Laxmi YRS, Okamoto K, Kim HJ, et al. 2011. Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogen. Int. J. Cancer 128(4):974-82
18. Degorce SL, Bailey A, Callis R, De Savi C, Ducray R, et al. 2015. Investigation of (E)-3-[4-(2-oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic acids as oral selective estrogen receptor down-regulators. J. Med. Chem. 58(8):3522-33
19. Scott JS, Bailey A, Davies R, Degorce SL, MacFaul PA, et al. 2016. Tetrahydroisoquinoline phenols: selective estrogen receptor downregulator antagonists with oral bioavailability in rat. ACS Med. Chem. Lett. 7(1):94-99
20. Garner F, Shomali M, Paquin D, Lyttle CR, Hattersley G. 2015. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anti-Cancer Drugs 26(9):948-56
21. Zhao Z, Wang L, James T, Jung Y, Kim I, et al. 2015. Reciprocal regulation of ERand ERstability and activity by diptoindonesin G. Chem. Biol. 22(12):1608-21
22. Wu Y-L, Yang X, Ren Z, McDonnell DP, Norris JD, et al. 2005. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol. Cell 18(4):413-24
23. Wittmann BM, Sherk A, McDonnell DP. 2007. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res. 67(19):9549-60
24. Bartlett JB, Dredge K, Dalgleish AG. 2004. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4(4):314-22
25. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau J, et al. 2007. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357(21):2123-32
26. Miguel JS,Weisel K,Moreau P, Lacy M, Song K, et al. 2013. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 14(11):1055-66
27. Hagner PR, Man HW, Fontanillo C, Wang M, Couto S, et al. 2015. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood 126(6):779-89
28. ItoT, AndoH, SuzukiT, Ogura T, Hotta K, et al. 2010. Identification of a primary target of thalidomide teratogenicity. Science 327(5971):1345-50
29. Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, et al. 2014. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343(6168):301-5
30. Lu G, Middleton RE, Sun H, NaniongM,Ott CJ, et al. 2014. Themyeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343(6168):305-9
31. Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, et al. 2014. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN. Br. J. Haematol. 164(6):811-21
32. Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, et al. 2015. Lenalidomide induces ubiquitination and degradation of CK1in del(5q) MDS. Nature 523(7559):183-88
33. Shaffer AL, EmreNCT, Lamy L,Ngo VN,Wright G, et al. 2008. IRF4 addiction in multiple myeloma. Nature 454(7201):226-31
34. Yang Y, Shaffer AL, Emre NCT, Ceribelli M, Zhang M, et al. 2012. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21(6):723-37
35. Schneider R, Ademà V, Heckl D, Jära°s M, Mallo M, et al. 2014. Role of casein kinase 1a1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 26(4):509-20
36. Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, et al. 2014. Structure of the human cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 21(9):803-9
37. Fischer ES, Böhm K, Lydeard JR, Yang H, Stadler MB, et al. 2014. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512(7512):49-53
38. Petzold G, Fischer ES, ThomäNH. 2016. Structural basis of lenalidomide-induced CK1degradation by the CRL4CRBN ubiquitin ligase. Nature 532:127-30
39. Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. 2001. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. PNAS 98(15):8554-59
40. Schneekloth JS Jr., Fonseca FN, Koldobskiy M, Mandal A, Deshaies R, et al. 2004. Chemical genetic control of protein levels: selective in vivo targeted degradation. J. Am. Chem. Soc. 126(12):3748-54
41. Schneekloth AR, Pucheault M, Tae HS, Crews CM. 2008. Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics. Bioorg. Med. Chem. Lett. 18(22):5904-8
42. Itoh Y, Kitaguchi R, Ishikawa M, Naito M, Hashimoto Y. 2011. Design, synthesis and biological evaluation of nuclear receptor-degradation inducers. Bioorg. Med. Chem. 19(22):6768-78
43. Hines J, Gough JD, Corson TW, Crews CM. 2013. Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs. PNAS 110(22):8942-47
44. Fan X, Jin WY, Lu J,Wang J,Wang YT. 2014. Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. Nat. Neurosci. 17(3):471-80
45. Okuhira K, Demizu Y, Hattori T, Ohoka N, Shibata N, et al. 2016. Molecular design, synthesis, and evaluation of SNIPER(ER) that induces proteasomal degradation of ER. Methods Mol. Biol. 1366:549-60
46. Okuhira K, Ohoka N, Sai K, Nishimaki-Mogami T, Itoh Y, et al. 2011. Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein. FEBS Lett. 585(8):1147-52
47. Sekine K, Takubo K, Kikuchi R, Nishimoto M, Kitagawa M, et al. 2008. Small molecules destabilize cIAP1 by activating auto-ubiquitylation. J. Biol. Chem. 283(14):8961-68
48. Zhang D, Baek SH, Ho A, Kim K. 2004. Degradation of target protein in living cells by small-molecule proteolysis inducer. Bioorg. Med. Chem. Lett. 14(3):645-48
49. Min J-H, Yang H, Ivan M, Gertler F, Kaelin WG, Pavletich NP. 2002. Structure of an HIF-1-pVHL complex: hydroxyproline recognition in signaling. Science 296(5574):1886-89
50. Buckley DL, Van Molle I, Gareiss PC, Tae HS, Michel J, et al. 2012. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1 interaction. J. Am. Chem. Soc. 134(10):4465-68
51. Galdeano C, Gadd MS, Soares P, Scaffidi S, Van Molle I, et al. 2014. Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities. J. Med. Chem. 57(20):8657-63
52. Zengerle M, Chan K-H, Ciulli A. 2015. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem. Biol. 10(8):1770-77
53. Bondeson DP, Mares A, Smith IED, Ko E, Campos S, et al. 2015. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11(8):611-17
54. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6):904-17
55. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, et al. 2010. Selective inhibition of BET bromodomains. Nature 468(7327):1067-73
56. Abbott DW, Wilkins A, Asara JM, Cantley LC. 2004. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr. Biol. 14(24):2217-27
57. Kobayashi K, Inohara N, Hernandez LD, Galán JE, Núñez G, et al. 2002. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416(6877):194-99
58. Huss JM, Gigue V, Kelly DP. 2004. Estrogen-related receptor directs peroxisome proliferatoractivated receptor signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol. Cell. Biol. 24(20):9079-91
59. Elangovan S, Ramachandran S, Venkatesan N, Ananth S, Gnana-Prakasam JP, et al. 2011. SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptorin breast cancer. Cancer Res. 71(21):6654-64
60. Patch RJ, Searle LL, Kim AJ, De D, Zhu X, et al. 2011. Identification of diaryl ether-based ligands for estrogen-related receptor as potential antidiabetic agents. J. Med. Chem. 54(3):788-808
61. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, et al. 2010. Suppression of inflammation by a synthetic histone mimic. Nature 468(7327):1119-23
62. Lu J, Qian Y, Altieri M, Dong H, Wang J, et al. 2015. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22(6):755-63
63. Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, et al. 2015. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348(6241):1376-81
64. Lai AC, ToureM, Hellerschmied D, Salami J, Jaime-Figueroa S, et al. 2016. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew. Chem. Int. Ed. 55(2):807-10
65. Corbin AS, Agarwal A, LoriauxM, Cortes J, Deininger MW, Druker BJ. 2011. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Investig. 121(1):396-409
66. Zhang H, Peng C, Hu Y, Li H, Sheng Z, et al. 2012. The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat. Genet. 44(8):861-71
67. Fischer ES, Scrima A, Böhm K, Matsumoto S, Lingaraju GM, et al. 2011. The molecular basis of CRL4DDB2/CSA ubiquitin ligase architecture, targeting, and activation. Cell 147(5):1024-39
68. Mattiroli F, Sixma TK. 2014. Lysine-targeting specificity in ubiquitin and ubiquitin-like modification pathways. Nat. Struct. Mol. Biol. 21(4):308-16
69. Xie T, Lim SM, Westover KD, Dodge ME, Ercan D, et al. 2014. Pharmacological targeting of the pseudokinase Her3. Nat. Chem. Biol. 10(12):1006-12
70. Gustafson JL, Neklesa TK, Cox CS, Roth AG, Buckley DL, et al. 2015. Small-molecule-mediated degradation of the androgen receptor through hydrophobic tagging. Angew. Chem. Int. Ed. 54(33):9659-62
71. Long MJC, Gollapalli DR, Hedstrom L. 2012. Inhibitor mediated protein degradation. Chem. Biol. 19(5):629-37
72. Coffey RT, Shi Y, Long MJCC, MarrMTII, Hedstrom L. 2016. Ubiquilin mediated small molecule inhibition of mammalian target of rapamycin complex 1(mTORC1)signaling. J. Biol.Chem. 291(10):5221-33
73. Lim SM, Xie T, Westover KD, Ficarro SB, Tae HS, et al. 2015. Development of small molecules targeting the pseudokinase Her3. Bioorg. Med. Chem. Lett. 25(16):3382-89
74. Huggins C, Hodges CV. 1941. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 168(1):293-97
75. Bradbury RH, Hales NJ, Rabow AA, Walker GE, Acton DG, et al. 2011. Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer. Bioorg. Med. Chem. Lett. 21(18):5442-45
76. Omlin A, Jones RJ, van der Noll R, Satoh T, Niwakawa M, et al. 2015. AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer-results of two parallel first-in-human phase I studies. Investig. New Drugs 33(3):679-90
77. Loddick SA,Ross SJ, Thomason AG, RobinsonDM,Walker GE, et al. 2013. AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol. Cancer Ther. 12:1715-27
78. Gray WM, Kepinski S, Rouse D, Leyser O, Estelle M. 2001. Auxin regulates SCFTIR1-dependent degradation of AUX/IAA proteins. Nature 414(6861):271-76
79. Tan X, Calderon-Villalobos LIA, Sharon M, Zheng C, Robinson CV, et al. 2007. Mechanism of auxin perception by the TIR1 ubiquitin ligase. Nature 446(7136):640-45
80. NishimuraK, FukagawaT,TakisawaH, KakimotoT, KanemakiM. 2009. An auxin-based degron system for the rapid depletion of proteins in nonplant cells. Nat. Methods 6(12):917-22
81. Holland AJ, Fachinetti D, Han JS, Cleveland DW. 2012. Inducible, reversible system for the rapid and complete degradation of proteins in mammalian cells. PNAS 109(49):E3350-57
82. Morawska M, Ulrich HD. 2013. An expanded tool kit for the auxin-inducible degron system in budding yeast. Yeast 30(9):341-51
83. McKinley KL, Sekulic N, Guo LY, Tsinman T, Black BE, Cheeseman IM. 2015. The CENP-L-N complex forms a critical node in an integrated meshwork of interactions at the centromere-kinetochore interface. Mol. Cell 60(6):886-98
84. Fachinetti D, Han JS, McMahon MA, Ly P, Abdullah A, et al. 2015. DNA sequence-specific binding of CENP-B enhances the fidelity of human centromere function. Dev. Cell 33(3):314-27
85. Philip N, Waters AP. 2015. Conditional degradation of Plasmodium calcineurin reveals functions in parasite colonization of both host and vector. Cell Host Microbe 18(1):122-31
86. Zhang L, Ward JD, Cheng Z, Dernburg AF. 2015. The auxin-inducible degradation (AID) system enables versatile conditional protein depletion in C. Elegans. Development 142:4374-84
87. TaeHS, Sundberg TB,Neklesa TK,Noblin DJ, Gustafson JL, et al. 2012. Identification of hydrophobic tags for the degradation of stabilized proteins. ChemBioChem. 13(4):538-41
88. Neklesa TK, Noblin DJ, Kuzin A, Lew S, Seetharaman J, et al. 2013. A bidirectional system for the dynamic small molecule control of intracellular fusion proteins. ACS Chem. Biol. 8(10):2293-300
89. Neklesa TK, Tae HS, Schneekloth AR, Stulberg MJ, Corson TW, et al. 2011. Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins. Nat. Chem. Biol. 7(8):538-43
90. Raina K, Noblin DJ, Serebrenik YV, Adams A, Zhao C, Crews CM. 2014. Targeted protein destabilization reveals an estrogen-mediated ER stress response. Nat. Chem. Biol. 10(11):957-62
91. Buckley DL, Raina K, Darricarrerre N, Hines J, Gustafson JL, et al. 2015. HaloPROTACs: use of small molecule PROTACs to induce degradation of HaloTag fusion proteins. ACS Chem. Biol. 10(8):1831-37
92. Tomoshige S, Naito M, Hashimoto Y, Ishikawa M. 2015. Degradation of HaloTag-fused nuclear proteins using bestatin-HaloTag ligand hybrid molecules. Org. Biomol. Chem. 13(38):9746-50
93. Chung HK, Jacobs CL, Huo Y, Yang J, Krumm SA, et al. 2015. Tunable and reversible drug control of protein production via a self-excising degron. Nat. Chem. Biol. 11(9):713-20
94. Yan D, Weisshaar M, Lamb K, Chung HK, Lin MZ, Plemper RK. 2015. Replication-competent influenza virus and respiratory syncytial virus luciferase reporter strains engineered for co-infections identify antiviral compounds in combination screens. Biochemistry 54(36):5589-604
95. Dvorin JD, Martyn DC, Patel SD, Grimley JS, Collins R, et al. 2011. A plant-like kinase in Plasmodium falciparum regulates parasite egress from erythrocytes. Science 328(5980):910-12
96. Cho U, Zimmerman SM, Chen L, Owen E, Kim JV, et al. 2013. Rapid and tunable control of protein stability in Caenorhabditis elegans using a small molecule. PLOS ONE 8(8):e72393
97. Froschauer A, Kube L, Kegler A, Rieger C, Gutzeit HO. 2015. Tunable protein stabilization in vivo mediated by Shield-1 in transgenic medaka. PLOS ONE 10(7):e0131252
98. Auffenberg E, Jurik A,Mattusch C, Stoffel R, Genewsky A, et al. 2016. Remote and reversible inhibition of neurons and circuits by small molecule induced potassium channel stabilization. Sci. Rep. 6:19293
99. Miyazaki Y, Chen L-C, Chu BW, Swigut T, Wandless TJ. 2015. Distinct transcriptional responses elicited by unfolded nuclear or cytoplasmic protein in mammalian cells. eLife 4:e07687
100. Lau HD, Yaegashi J, Zaro BW, Pratt MR. 2010. Precise control of protein concentration in living cells. Angew. Chem. Int. Ed. 49(45):8458-61
101. Lin YH, PrattMR. 2014. A dual small-molecule rheostat for precise control of protein concentration in mammalian cells. ChemBioChem. 15(6):805-9
102. Niesen FH, Berglund H, Vedadi M. 2007. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2(9):2212-21
103. Van Molle I, Thomann A, Buckley DL, So EC, Lang S, et al. 2012. Dissecting fragment-based lead discovery at the vonHippel-Lindau protein:hypoxia inducible factor 1protein-protein interface. Chem. Biol. 19(10):1300-12
104. ComessKM,Sun C, Abad-ZapateroC,Goedken ER,GumRJ, et al. 2011. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. ACS Chem. Biol. 6(3):234-44
105. Ludlow RF, Verdonk ML, Saini HK, Tickle IJ, Jhoti H. 2015. Detection of secondary binding sites in proteins using fragment screening. PNAS 112(52):15910-15
106. Cimermancic P, Weinkam P, Rettenmaier TJ, Bichmann L, Keedy DA, et al. 2016. CryptoSite: expanding the druggable proteome by characterization and prediction of cryptic binding sites. J. Mol. Biol. 428(4):709-19
107. Milroy LG, Grossmann TN, Hennig S, Brunsveld L, Ottmann C. 2014. Modulators of protein-protein interactions. Chem. Rev. 114(9):4695-748
108. Aghajan M, Jonai N, Flick K, Fu F, Luo M, et al. 2010. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat. Biotechnol. 28(7):738-42
109. Park S, Ntai I, Thomas P, Konishcheva E, Kelleher NL, Statsuk AV. 2012. Mechanism-based small molecule cross-linkers of HECT E3 ubiquitin ligase-substrate pairs. Biochemistry 51(42):8327-29
110. Landré V, Rotblat B, Melino S, Bernassola F, Melino G. 2014. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities. Oncotarget 5(18):7988-8013
111. Hirota T, Lee JW, St. John PC, Sawa M, Iwaisako K, et al. 2012. Identification of small molecule activators of cryptochrome. Science 337(6098):1094-97
112. Orlicky S, Tang X, Neduva V, Elowe N, Brown ED, et al. 2010. An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase. Nat. Biotechnol. 28(7):733-37